StockData
Lipocine Inc. logo

Lipocine Inc. (LPCN) stock

LPCNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3039% below fair value
$1.60−0.06 (-3.61%)

Close on Nov 17, 2026Market cap $13.19MP/E –Yield –

Lipocine total assets

Total assets on the balance sheet at the end of each period.

Lipocine's total assets was $23.84M at Jun 30, 2026. For fiscal 2025 it was $17.01M, down 24.5% from the year before. Over ten years it grew -9.3% a year on average. The highest annual figure on record is $52.48M in fiscal 2021.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$17.01M-24.5%
FY2024Dec 31, 2024$22.51M-2.1%
FY2023Dec 31, 2023$23.00M-38.7%
FY2022Dec 31, 2022$37.54M-28.5%
FY2021Dec 31, 2021$52.48M+107.0%
FY2020Dec 31, 2020$25.35M+29.0%
FY2019Dec 31, 2019$19.66M-5.7%
FY2018Dec 31, 2018$20.85M-17.7%
FY2017Dec 31, 2017$25.33M-7.4%
FY2016Dec 31, 2016$27.34M-39.7%
FY2015Dec 31, 2015$45.38M+62.1%
FY2014Dec 31, 2014$27.99M-39.3%
FY2013Dec 31, 2013$46.11M+728.3%
FY2012Dec 31, 2012$5.57M+17056.9%
FY2011Dec 31, 2011$32.44K–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$23.84M+28.3%
Q1 FY2026Mar 31, 2026$25.36M+23.7%
Q4 FY2025Dec 31, 2025$17.01M-24.5%
Q3 FY2025Sep 30, 2025$16.07M-22.3%
Q2 FY2025Jun 30, 2025$18.58M-19.3%
Q1 FY2025Mar 31, 2025$20.50M-19.4%
Q4 FY2024Dec 31, 2024$22.51M-2.1%
Q3 FY2024Sep 30, 2024$20.70M-16.4%
Q2 FY2024Jun 30, 2024$23.03M-24.4%
Q1 FY2024Mar 31, 2024$25.45M-25.2%
Q4 FY2023Dec 31, 2023$23.00M-38.7%
Q3 FY2023Sep 30, 2023$24.75M-37.2%
Q2 FY2023Jun 30, 2023$30.48M-27.8%
Q1 FY2023Mar 31, 2023$34.02M-28.5%
Q4 FY2022Dec 31, 2022$37.54M-28.5%
Q3 FY2022Sep 30, 2022$39.42M-2.4%
Q2 FY2022Jun 30, 2022$42.19M-10.6%
Q1 FY2022Mar 31, 2022$47.60M-5.9%
Q4 FY2021Dec 31, 2021$52.48M+107.0%
Q3 FY2021Sep 30, 2021$40.39M+63.2%
Q2 FY2021Jun 30, 2021$47.18M+100.9%
Q1 FY2021Mar 31, 2021$50.58M+140.9%
Q4 FY2020Dec 31, 2020$25.35M+29.0%
Q3 FY2020Sep 30, 2020$24.75M+42.7%
Q2 FY2020Jun 30, 2020$23.49M+19.4%
Q1 FY2020Mar 31, 2020$20.99M-8.7%
Q4 FY2019Dec 31, 2019$19.66M-5.7%
Q3 FY2019Sep 30, 2019$17.34M-23.6%
Q2 FY2019Jun 30, 2019$19.68M-22.2%
Q1 FY2019Mar 31, 2019$22.99M-27.4%
Q4 FY2018Dec 31, 2018$20.85M-17.7%
Q3 FY2018Sep 30, 2018$22.69M-13.6%
Q2 FY2018Jun 30, 2018$25.30M-9.8%
Q1 FY2018Mar 31, 2018$31.68M+16.4%
Q4 FY2017Dec 31, 2017$25.33M-7.4%
Q3 FY2017Sep 30, 2017$26.26M-11.2%
Q2 FY2017Jun 30, 2017$28.05M–
Q1 FY2017Mar 31, 2017$27.22M–
Q4 FY2016Dec 31, 2016$27.34M–
Q3 FY2016Sep 30, 2016$29.55M–

More Lipocine figures

See a number that looks wrong?